Prohibit the use of spread pricing by pharmacy benefit managers
Minnesota bill bans pharmacy benefit managers from profiting on price differences between pharmacy reimbursement and insurer charges, aiming to lower drug costs.
Minnesota bill bans pharmacy benefit managers from profiting on price differences between pharmacy reimbursement and insurer charges, aiming to lower drug costs.
SF 4062 would prohibit pharmacy benefit managers (PBMs) from using "spread pricing," a practice where PBMs pocket the difference between what they reimburse pharmacies and what they charge insurers or consumers for prescription medications. The bill aims to increase transparency and reduce hidden costs in the pharmacy supply chain by eliminating this profit mechanism.
Spread pricing is considered a major driver of pharmacy costs and has been identified as a significant source of PBM revenue that doesn't directly fund patient care or pharmacy operations. Prohibiting this practice could lower prescription drug costs for consumers and reduce financial pressure on independent pharmacies, which are particularly vulnerable to narrow PBM reimbursement rates. This aligns with ongoing national scrutiny of PBM business practices that have faced criticism from pharmacists, patients, and policymakers across party lines.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.